Immunogenicity and Protective Efficacy of Oligomeric Human Immunodeficiency Virus Type 1 gp140
Open Access
- 15 January 2001
- journal article
- Published by American Society for Microbiology in Journal of Virology
- Vol. 75 (2), 645-653
- https://doi.org/10.1128/jvi.75.2.645-653.2001
Abstract
The biologically active form of the human immunodeficiency virus type 1 (HIV-1) envelope (Env) glycoprotein is oligomeric. We previously described a soluble HIV-1 IIIB Env protein, gp140, with a stable oligomeric structure composed of uncleaved gp120 linked to the ectodomain of gp41 (P. L. Earl, C. C. Broder, D. Long, S. A. Lee, J. Peterson, S. Chakrabarti, R. W. Doms, and B. Moss, J. Virol. 68:3015–3026, 1994). Here we compared the antibody responses of rabbits to gp120 and gp140 that had been produced and purified in an identical manner. The gp140 antisera exhibited enhanced cross-reactivity with heterologous Env proteins as well as greater neutralization of HIV-1 compared to the gp120 antisera. To examine both immunogenicity and protective efficacy, we immunized rhesus macaques with oligomeric gp140. Strong neutralizing antibodies against a homologous virus and modest neutralization of heterologous laboratory-adapted isolates were elicited. No neutralization of primary isolates was observed. However, a substantial fraction of the neutralizing activity could not be blocked by a V3 loop peptide. After intravenous challenge with simian-HIV virus SHIV-HXB2, three of the four vaccinated macaques exhibited no evidence of virus replication.Keywords
This publication has 130 references indexed in Scilit:
- Generation and Structural Analysis of Soluble Oligomeric gp140 Envelope Proteins Derived from Neutralization-Resistant and Neutralization-Susceptible Primary HIV Type 1 IsolatesAIDS Research and Human Retroviruses, 2000
- Prechallenge High Neutralizing Antibodies and Long-Lasting Immune Reactivity to gp41 Correlate With Protection of Rhesus Monkeys Against Productive Simian Immunodeficiency Virus Infection or Disease DevelopmentJAIDS Journal of Acquired Immune Deficiency Syndromes, 1998
- Induction of immune responses to HIV-1 by canarypox virus (ALVAC) HIV-1 and gp120 SF-2 recombinant vaccines in uninfected volunteersAIDS, 1998
- Cytotoxic T Cell and Neutralizing Antibody Responses to Human Immunodeficiency Virus Type 1 Envelope with a Combination Vaccine RegimenThe Journal of Infectious Diseases, 1998
- HIV Type 1 Vaccine-Induced Cytotoxic T Cell Responses in Phase I Clinical Trials: Detection, Characterization, and QuantitationAIDS Research and Human Retroviruses, 1997
- A Dual-Tropic Primary HIV-1 Isolate That Uses Fusin and the β-Chemokine Receptors CKR-5, CKR-3, and CKR-2b as Fusion CofactorsCell, 1996
- Utility of SHIV for Testing HIV-1 Vaccine Candidates in MacaquesJAIDS Journal of Acquired Immune Deficiency Syndromes, 1996
- Determinants Of Antibody Response After Recombinant Gp160 Boosting In Vaccinia-Naive Volunteers Primed With Gp160-Recombinant Vaccinia VirusThe Journal of Infectious Diseases, 1994
- V3-specific neutralizing antibodies in sera from HIV-1 gp160-immunized volunteers block virus fusion and act synergistically with human monoclonal antibody to the conformation-dependent CD4 binding site of gp120. NIH-NIAID AIDS Vaccine Clinical Trials Network.Journal of Clinical Investigation, 1993
- Antibody Epitopes Sensitive to the State of Human Immunodeficiency Virus Type 1 gp41 Oligomerization Map to a Putative α-Helical RegionAIDS Research and Human Retroviruses, 1992